Derek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 986 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.03, for a total value of $27,637.58. Following the completion of the sale, the insider now directly owns 80,818 shares of the company’s stock, valued at approximately $2,265,328.54. The trade was a 1.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Castle Biosciences Trading Down 1.7 %

Castle Biosciences stock opened at $25.02 on Thursday. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The firm has a market capitalization of $700.81 million, a PE ratio of 125.11 and a beta of 0.92. The business’s 50-day simple moving average is $29.55 and its 200-day simple moving average is $28.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. The company had revenue of $85.78 million during the quarter, compared to analyst estimates of $78.55 million. During the same period in the previous year, the company earned ($0.26) earnings per share. Equities research analysts forecast that Castle Biosciences, Inc. will post 0.34 earnings per share for the current year.

Institutional Trading of Castle Biosciences

A number of hedge funds have recently bought and sold shares of CSTL. Green Alpha Advisors LLC bought a new position in shares of Castle Biosciences during the 4th quarter worth about $249,000. JPMorgan Chase & Co. increased its stake in Castle Biosciences by 165.2% during the third quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company’s stock valued at $1,980,000 after acquiring an additional 43,241 shares during the period. Principal Financial Group Inc. increased its stake in Castle Biosciences by 2.7% during the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after acquiring an additional 40,377 shares during the period. Franklin Resources Inc. raised its holdings in Castle Biosciences by 87.3% in the 3rd quarter. Franklin Resources Inc. now owns 69,382 shares of the company’s stock valued at $1,979,000 after acquiring an additional 32,344 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Castle Biosciences by 310.7% in the 3rd quarter. Barclays PLC now owns 52,301 shares of the company’s stock worth $1,491,000 after acquiring an additional 39,567 shares during the period. 92.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have commented on CSTL shares. Lake Street Capital boosted their target price on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. KeyCorp upped their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Canaccord Genuity Group raised their target price on Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, October 29th. BTIG Research upped their price target on Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Scotiabank raised their price objective on Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday, November 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $40.29.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.